{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:11:13Z","timestamp":1790313073804,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitor therapy for cancer treatment can give rise to a variety of adverse events. Here we report a male patient with metastatic melanoma who experienced life-threatening colitis and duodenitis following treatment with ipilimumab and nivolumab. The patient did not respond to the first three lines of immunosuppressive therapy (corticosteroids, infliximab, and vedolizumab), but recovered well after administration of tofacitinib, a JAK inhibitor. Cellular and transcriptional data on colon and duodenum biopsies shows significant inflammation in the tissue, characterized by a large number of CD8 T cells and high expression of PD-L1. While cellular numbers do decrease during three lines of immunosuppressive therapy, CD8 T cells remain relatively high in the epithelium, along with PD-L1 expression in the involved tissue and expression of colitis-associated genes, indicating an ongoing colitis at that moment. Despite all immunosuppressive treatments, the patient has an ongoing tumor response with no evidence of disease. Tofacitinib might be a good candidate to consider more often for ipilimumab\/nivolumab-induced colitis.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1212432","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T10:05:48Z","timestamp":1687773948000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib"],"prefix":"10.3389","volume":"14","author":[{"given":"Mark W. D.","family":"Sweep","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J. H.","family":"Tjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A. J.","family":"Gorris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalijn F.","family":"Bol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Westdorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"New Engl J Med"},{"key":"B8","article-title":"The mechanism of action of tofacitinib - an oral janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"103444","DOI":"10.1016\/j.isci.2021.103444","article-title":"Retinoic acid signaling drives differentiation toward the absorptive lineage in colorectal cancer","volume":"24","author":"Wester","year":"2021","journal-title":"iScience"},{"key":"B10","volume-title":"seq2science. 0.9.5 ed","author":"Van der Sande","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxw041","article-title":"False discovery rates: a new deal","volume":"18","author":"Stephens","year":"2016","journal-title":"Biostatistics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1113","article-title":"The gene ontology resource: enriching a GOld mine","volume":"49","author":"Carbon","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an r package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics"},{"key":"B15","unstructured":"YuG\n          Enrichplot: visualization of functional enrichment result. 1.18.3 ed"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn653","article-title":"PID: the pathway interaction database","volume":"37","author":"Schaefer","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"B17","article-title":"Gene indexing: characterization and analysis of NLM's GeneRIFs","volume":"2003","author":"Mitchell","year":"2003","journal-title":"AMIA Annu Symp Proc"},{"key":"B18","unstructured":"KoldeR\n          Pheatmap: pretty heatmaps. 1.0.12 ed"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004329","article-title":"Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome","volume":"10","author":"Gorris","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"10.22.464548","DOI":"10.1101\/2021.10.22.464548","article-title":"A segmentation-free machine learning architecture for immune land-scape phenotyping in solid tumors by multichannel imaging","volume":"2021","author":"Sultan","year":"2021","journal-title":"bioRxiv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.768957","article-title":"Mechanisms of immune checkpoint inhibitor-mediated colitis","volume":"12","author":"Westdorp","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/his.14115","article-title":"Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics","volume":"77","author":"Cassol","year":"2020","journal-title":"Histopathology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07598-2","article-title":"CD8(+) lymphocyte infiltration is a specific feature of colitis induced by immune checkpoint inhibitors","volume":"68","author":"Takahashi","year":"2023","journal-title":"Digest Dis Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-011-0325-6","article-title":"PI3K\/Akt signaling pathway is involved in the pathogenesis of ulcerative colitis","volume":"60","author":"Huang","year":"2011","journal-title":"Inflammation Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.08.023","article-title":"Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production","volume":"131","author":"Tamaki","year":"2006","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"114153","DOI":"10.1016\/j.bcp.2020.114153","article-title":"Caveolin-1 protects against DSS-induced colitis through inhibiting intestinal nitrosative stress and mucosal barrier damage in mice","volume":"180","author":"Song","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.prostaglandins.2018.12.002","article-title":"Inhibition of ASM activity ameliorates DSS-induced colitis in mice","volume":"140","author":"Xiong","year":"2019","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1053\/j.gastro.2020.10.029","article-title":"Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis","volume":"160","author":"Bishu","year":"2021","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2002527","article-title":"Tofacitinib for refractory immune-related colitis from PD-1 therapy","volume":"382","author":"Esfahani","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2022-000989","article-title":"Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report","volume":"9","author":"Holmstroem","year":"2022","journal-title":"BMJ Open Gastroenterol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1212432\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T10:05:52Z","timestamp":1687773952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1212432\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2023.1212432"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1212432","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"article-number":"1212432"}}